Guardion Health Sciences, Inc. — Cyborg Score 2/10
Challenged
Clinical nutrition and dietary supplements (historical)
Strategic Profile
The company previously focused on ocular health products including GlaucoCetin and Lumega-Z, but shifted to a liquidation model after selling its Viactiv® brand for $17.2 million gross cash consideration in 2024. The company completed its Nasdaq delisting in October 2024 and now trades OTC as it executes its dissolution plan.
Cyborg Score Rationale
The company is undergoing systematic liquidation and asset disposition. With core business lines divested and operations winding down, Guardion lacks growth drivers and operational momentum. The liquidation status makes this a distressed situation rather than a going concern.
Top Insights
(Q2 2024) Viactiv brand sale generated $17.2M in gross proceeds to fund shareholder distributions
(October 2024) Completed delisting from Nasdaq; now trades OTC following shareholder approval of liquidation plan
Focused on ocular health products (GlaucoCetin, Lumega-Z) prior to strategic exit and brand divestiture
Significantly reduced operational scale post-Viactiv sale with minimal ongoing revenue generation
Named Competitors
Lutein/Zeaxanthin Supplements — Ocular health supplements
Recent Developments
(June 2024) Stockholders approved Plan of Liquidation and Dissolution
(Q2 2024) Sale of Viactiv® brand to Doctor's Best Inc. completed for $17.2M gross cash
(October 2024) Delisting from Nasdaq Capital Market; appointed Mark Goldstone as Interim President and CEO
Open the full interactive Guardion Health Sciences, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.